• 1
    Pass HI, Vogelzang N, Hahn S, Carbone M. Malignant pleural mesothelioma. Curr Probl Cancer 2004; 28: 93174.
  • 2
    Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591603.
  • 3
    Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002; 29: 217.
  • 4
    Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 263644.
  • 5
    Van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 68819.
  • 6
    Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol 2008; 9: 14757.
  • 7
    Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009; 27: 208190.
  • 8
    Liu W, Ernst JD, Broaddus VC. Phagocytosis of crocidolite asbestos induces oxidative stress, DNA damage, and apoptosis in mesothelial cells. Am J Respir Cell Mol Biol 2000; 23: 3718.
  • 9
    Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366: 397408.
  • 10
    Faux SP, Houghton CE, Hubbard A, Patrick G. Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres. Carcinogenesis 2000; 21: 227580.
  • 11
    Kratzke RA, Otterson GA, Lincoln CE et al. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 1995; 87: 18705.
  • 12
    Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995; 11: 5115.
  • 13
    Cheng JQ, Jhanwar SC, Klein WM et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54: 554751.
  • 14
    Taniguchi T, Karnan S, Fukui T et al. Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci 2007; 98: 43846.
  • 15
    Altomare DA, Menges CW, Pei J et al. Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. Proc Natl Acad Sci U S A 2009; 106: 34205.
  • 16
    Sekido Y, Pass HI, Bader S et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995; 55: 122731.
  • 17
    Bianchi AB, Mitsunaga SI, Cheng JQ et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A 1995; 92: 108548.
  • 18
    Baser ME. The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat 2006; 27: 297306.
  • 19
    Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 2009; 64: 1407.
  • 20
    Guled M, Lahti L, Lindholm PM et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis. Genes Chromosomes Cancer 2009; 48: 61523.
  • 21
    Altomare DA, Vaslet CA, Skele KL et al. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 2005; 65: 80905.
  • 22
    Jongsma J, Van Montfort E, Vooijs M et al. A conditional mouse model for malignant mesothelioma. Cancer Cell 2008; 13: 26171.
  • 23
    Scoles DR. The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta 2008; 1785: 3254.
  • 24
    Jin H, Sperka T, Herrlich P, Morrison H. Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature 2006; 442: 5769.
  • 25
    Hamaratoglu F, Willecke M, Kango-Singh M et al. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 2006; 8: 2736.
  • 26
    Zhao B, Lei QY, Guan KL. The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol 2008; 20: 63846.
  • 27
    Yokoyama T, Osada H, Murakami H et al. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis 2008; 29: 213946.
  • 28
    Camargo FD, Gokhale S, Johnnidis JB et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007; 17: 205460.
  • 29
    Downward J, Basu S. YAP and p73: a complex affair. Mol Cell 2008; 32: 74950.
  • 30
    Zhao B, Ye X, Yu J et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008; 22: 196271.
  • 31
    López-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG. Loss of the Tumor Suppressor NF2, encoding Merlin, Constitutively Activates Integrin-dependent mTORC1 Signaling. Mol Cell Biol 2009; 29: 423549.
  • 32
    Jagadeeswaran R, Ma PC, Seiwert TY et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006; 66: 35261.
  • 33
    Destro A, Ceresoli GL, Falleni M et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 2006; 51: 20715.
  • 34
    Altomare DA, You H, Xiao GH et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005; 24: 60809.
  • 35
    Suzuki Y, Murakami H, Kawaguchi K et al. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep 2009; 2: 1818.
  • 36
    Thomas RK, Baker AC, Debiasi RM et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39: 34751.
  • 37
    Govindan R, Kratzke RA, Herndon JE II et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005; 11: 23004.
  • 38
    Mathy A, Baas P, Dalesio O, Van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005; 50: 836.
  • 39
    Kawaguchi K, Murakami H, Taniguchi T et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 2009; 30: 1097105.
  • 40
    Galffy G, Mohammed KA, Dowling PA, Nasreen N, Ward MJ, Antony VB. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res 1999; 59: 36771.
  • 41
    Ramos-Nino ME, Blumen SR, Sabo-Attwood T et al. HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. Am J Respir Cell Mol Biol 2008; 38: 20917.
  • 42
    Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 1999; 180: 1507.
  • 43
    Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 1993; 53: 434955.
  • 44
    Balsara BR, Bell DW, Sonoda G et al. Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. Cancer Res 1999; 59: 4504.
  • 45
    Krismann M, Muller KM, Jaworska M, Johnen G. Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases. J Pathol 2002; 197: 36371.
  • 46
    Heintz NH, Janssen YM, Mossman BT. Persistent induction of c-fos and c-jun expression by asbestos. Proc Natl Acad Sci U S A 1993; 90: 3299303.
  • 47
    Mariani O, Brennetot C, Coindre JM et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell 2007; 11: 36174.
  • 48
    Ivanov SV, Miller J, Lucito R et al. Genomic events associated with progression of pleural malignant mesothelioma. Int J Cancer 2009; 124: 58999.
  • 49
    Singhal S, Wiewrodt R, Malden LD et al. Gene expression profiling of malignant mesothelioma. Clin Cancer Res 2003; 9: 308097.
  • 50
    Gordon GJ, Rockwell GN, Jensen RV et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 2005; 166: 182740.
  • 51
    Hoang CD, D’Cunha J, Kratzke MG et al. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 2004; 125: 184352.
  • 52
    Gordon GJ, Jensen RV, Hsiao LL et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003; 95: 598605.
  • 53
    Gray SG, Fennell DA, Mutti L, O’Byrne KJ. In arrayed ranks: array technology in the study of mesothelioma. J Thorac Oncol 2009; 4: 41125.
  • 54
    Roe OD, Anderssen E, Sandeck H, Christensen T, Larsson E, Lundgren S. Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer 2009; doi: 10.1016/jlungcan.2009.03.016.
  • 55
    Lee AY, He B, You L et al. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 2004; 23: 66726.
  • 56
    Destro A, Ceresoli GL, Baryshnikova E et al. Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient’s follow-up. Lung Cancer 2008; 59: 36976.
  • 57
    Christensen BC, Godleski JJ, Marsit CJ et al. Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis 2008; 29: 15559.
  • 58
    Christensen BC, Houseman EA, Godleski JJ et al. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res 2009; 69: 22734.
  • 59
    Busacca S, Germano S, De Cecco L et al. MicroRNA Signature of Malignant Mesothelioma with Potential Diagnostic and Prognostic Implications. Am J Respir Cell Mol Biol 2009; doi: 10.1165/rcmb.2009-0060OC.
  • 60
    Ascoli V, Cavone D, Merler E et al. Mesothelioma in blood related subjects: report of 11 clusters among 1954 Italy cases and review of the literature. Am J Ind Med 2007; 50: 35769.
  • 61
    Ugolini D, Neri M, Ceppi M et al. Genetic susceptibility to malignant mesothelioma and exposure to asbestos: the influence of the familial factor. Mutat Res 2008; 658: 16271.
  • 62
    Neri M, Ugolini D, Dianzani I et al. Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases. Mutat Res 2008; 659: 12636.
  • 63
    Carbone M, Emri S, Dogan AU et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer 2007; 7: 14754.
  • 64
    Fennell DA, Gaudino G, O’Byrne KJ, Mutti L, Van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008; 5: 13647.
  • 65
    Weder W, Stahel RA, Bernhard J et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18: 1196202.
  • 66
    Krug LM, Pass HI, Rusch VW et al. Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma. J Clin Oncol 2009; 27: 300713.
  • 67
    Kindler HL. Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol 2008; 9: 1719.
  • 68
    Ramalingam SS, Belani CP, Ruel C et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009; 4: 97101.
  • 69
    Sartore-Bianchi A, Gasparri F, Galvani A et al. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 2007; 13: 594251.
  • 70
    Beck AK, Pass HI, Carbone M, Yang H. Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies. Future Oncol 2008; 4: 3419.
  • 71
    Lopez-Rios F, Chuai S, Flores R et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006; 66: 29709.
  • 72
    Suzuki E, Kim S, Cheung HK et al. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 2007; 67: 23519.
  • 73
    Tabata C, Tabata R, Hirayama N et al. All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice. Eur Respir J 2009; doi: 10.1183/09031936.00195708.
  • 74
    Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008; 44: 4653.
  • 75
    Feng Y, Xiao X, Zhu Z et al. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther 2009; 8: 11138.
  • 76
    Inamoto T, Yamada T, Ohnuma K et al. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res 2007; 13: 4191200.
  • 77
    Usami N, Fukui T, Kondo M et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci 2006; 97: 38794.
  • 78
    Seidel C, Schagdarsurengin U, Blumke K et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 2007; 46: 86571.
  • 79
    Tapon N, Harvey KF, Bell DW et al. Salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 2002; 110: 46778.
  • 80
    Kawahara M, Hori T, Chonabayashi K, Oka T, Sudol M, Uchiyama T. Kpm/Lats2 is linked to chemosensitivity of leukemic cells through the stabilization of p73. Blood 2008; 112: 385666.
  • 81
    Strazisar M, Mlakar V, Glavac D. LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma. Lung Cancer 2009; 64: 25762.
  • 82
    Xu MZ, Yao TJ, Lee NP et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009; doi: 10.1002/cncr.24495.
  • 83
    Steinhardt AA, Gayyed MF, Klein AP et al. Expression of Yes-associated protein in common solid tumors. Hum Pathol 2008; 39: 15829.
  • 84
    Chan SW, Lim CJ, Guo K et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008; 68: 25928.